Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) [Yahoo! Finance]
Biodexa Pharmaceuticals plc - American Depositary Shares (BDRX)
Company Research
Source: Yahoo! Finance
Treatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding for Pivotal Phase 3 trial in FAP An estimated 100,000 in U.S. and Europe are afflicted with FAP, precancerous polyps that typically lead to surgical removal of the colon and/or rectum In FAP, eRapa holds the potential of delaying or preventing surgical intervention Multiple opportunities seen in other indications, including bladder and prostate cancers FAP is a substantially genetic orphan disease for which there are no approved therapeutic options; the current standard of care is surveillance and surgery Phase 3 FAP program is supported by a $17 million grant awarded from the Cancer Prevention and Research Institute of Texas (“CPRIT”) in a competitive process Phase 2 results in FAP to be presented at two leading scientific conferences in Q2 ‘24 Ongoing Phase 2 study in Non-muscle Invasive Bladder Cancer expected to read-out in Q2 ‘25 Phase 2 study
Show less
Read more
Impact Snapshot
Event Time:
BDRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BDRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BDRX alerts
High impacting Biodexa Pharmaceuticals plc - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
BDRX
News
- Posting of Annual Report & Notice of AGM - Total Voting Rights [Yahoo! Finance]Yahoo! Finance
- Posting of Annual Report & Notice of AGM - Total Voting RightsGlobeNewswire
- Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition [Yahoo! Finance]Yahoo! Finance
- Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous ConditionAccesswire
- Biodexa's Licensor Emtora to Announce Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis to be Presented at Prestigious 2024 Digestive Disease Week Annual Meeting [Yahoo! Finance]Yahoo! Finance
BDRX
Sec Filings
- 5/15/24 - Form 6-K
- 5/15/24 - Form 6-K
- 5/3/24 - Form 424B3
- BDRX's page on the SEC website